FGFR1 and hypogonadotropic hypogonadism: For instance, in metabolic kinasopathies, mutations in the insulin tyrosine kinase receptors lead to autosomal dominant insulin resistance with type 2 diabetes, metabolic dyslipidemia, lipodystrophy, and hepatic steatosis, whereas several loss-of-function mutations in fibroblast growth factor receptor 1 (also a tyrosine kinase) cause hypogonadotropic hypogonadism [23,24].